Navigation Links
Clinical Study of Intermezzo(R) for the Treatment of Middle of the Night Awakening Published in SLEEP
Date:10/22/2008

stration."

About the Proposed Transcept and Novacea Merger

On August 29, 2008, Transcept Pharmaceuticals, Inc. and Novacea, Inc. (Nasdaq: NOVC) entered into a definitive merger agreement under which Novacea will merge with Transcept in an all-stock transaction. Assuming a close near the end of 2008, the combined company is expected to have an estimated cash balance of $88 to $92 million. Further information on the merger agreement is available in the last section of this press release, entitled "Additional Information about the Merger and Where to Find It."

About SLEEP

SLEEP is the official publication of the Associated Professional Sleep Societies, LLC (APSS) a joint venture of the American Academy of Sleep Medicine and the Sleep Research Society. A reprint of the study can be viewed online at http://www.journalsleep.org/ViewAbstract.aspx?citationid=3662.

About Transcept Pharmaceuticals

Transcept Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the fields of psychiatry and sleep medicine. The lead Transcept product candidate, Intermezzo(R), is a sublingual low dose formulation of zolpidem that has been developed for use as-needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep. Intermezzo(R) Phase 3 clinical trials have been completed and, on September 30, 2008, Transcept submitted a New Drug Application for Intermezzo(R) to the U.S. Food and Drug Administration.

For further information, please visit the company's website at:
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
6. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
9. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
10. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
11. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  Spherix Incorporated (SPEX) ... fostering and monetization of intellectual property, today announced that ... period ending June 30, 2014 on Monday, August 18, ... at 10 a.m. ET on Monday, August 18, 2014 ... led by the company,s CEO, Anthony Hayes . ...
(Date:7/24/2014)... 2014 The patent provides substantially ... test results. It also enables true sample ID ... and reporting of high profile assays such as ... rapidly growing area of biotechnology that includes DNA ... and companion diagnostics in personalized medicine. The new ...
(Date:7/23/2014)... -- Sangamo BioSciences, Inc. (NASDAQ: SGMO ) today ... For the second quarter ended June ... $7.0 million, or $0.10 per share, compared to a ... for the same period in 2013. As of June ... securities and interest receivable of $236.7 million. ...
(Date:7/23/2014)... at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR), the Vienna University ... have succeeded in embedding nearly perfect semiconductor crystals ... of producing hybrid nanowires, very fast and multi-functional ... chip in the future. The research results will ... . , Nano-optoelectronics are considered the cornerstone of ...
Breaking Biology Technology:Spherix Schedules Shareholder Update Call 2New DNA-barcode Patent Virtually Eliminates False Test Results and Sample Mix-up 2Sangamo BioSciences Reports Second Quarter 2014 Financial Results 2Sangamo BioSciences Reports Second Quarter 2014 Financial Results 3Sangamo BioSciences Reports Second Quarter 2014 Financial Results 4Sangamo BioSciences Reports Second Quarter 2014 Financial Results 5Sangamo BioSciences Reports Second Quarter 2014 Financial Results 6Sangamo BioSciences Reports Second Quarter 2014 Financial Results 7Sangamo BioSciences Reports Second Quarter 2014 Financial Results 8Sangamo BioSciences Reports Second Quarter 2014 Financial Results 9A crystal wedding in the nanocosmos 2
... Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ONCY ) ("Oncolytics" or the "Company") ... ended March 31, 2010 . , ... "We have recently seen a range of ... mechanism of action and provided evidence of synergies with currently approved ...
... PARIS , May 12, 2010 , ... - New Outcomes Trial to Expand Evidence ... , ... of a multinational, randomized double-blind Phase IIIb trial,PALLAS, to assess the potential clinical benefit ...
... Scientists from Zymes LLC, the University of Windsor ... of Canada presented their research at the 2010 ... 28th .  The paper entitled, " Protection of SNpc neurons by ... disease: The role of neurotrophic factors," describes a potential treatment ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 2Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 3Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 4Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 5Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 6Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 7Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 8Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 9Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 2Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 3Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 4Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 5Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 6Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 7Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 8Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 9Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 10Zymes’ Water Soluble CoQ10 Decreases Symptoms in Animal Models of Parkinson’s Disease 2
(Date:7/24/2014)... hazard in the United States, wildland managers often utilize ... suppressed trees (ladder fuels). These cuttings and other ... fire danger in order to dispose of the material. ... managers often cover all or part of the debris ... agricultural plastic, in order to keep water out. A ...
(Date:7/24/2014)... in which life arose have been maintained in our cells ... , Research published today in the Journal of Biological ... likely also in animals still perform ancient reactions thought to ... four billion years ago. , The primordial soup theory suggests ... result of the combination of metals, gases from the atmosphere ...
(Date:7/24/2014)... Expanding on his work with a new drug that successfully ... of Houston has received a $250,000 grant to expand his ... effort to treat a wider range of autoimmune diseases., Chandra ... biomedical Engineering at UH, previously published a study in Arthritis ... that successfully treated lupus in mice and reduced the number ...
Breaking Biology News(10 mins):Study gives new perspective on agricultural plastic, debris burning, and air quality 2Biomedical engineer looks at new applications for novel lupus drug 2Biomedical engineer looks at new applications for novel lupus drug 3
... COLUMBIA Taking vitamin D supplements during pregnancy is not ... preterm labor/births and infections, according to results of a randomized ... (PAS) annual meeting in Vancouver, British Columbia, Canada. ... D could cause birth defects, according to Carol L. Wagner, ...
... UniversityCorpus Christi were astounded to find that seamounts, mountains that ... common ocean habitats in the world. Their findings are published ... prevalence of seamounts, which are treasure troves of marine biodiversity. ... never see a seamount, but this study shows that they ...
... of daily diet advice? If only we knew which ... new finding by a team of Cornell University researchers, dieters ... adhere to their diet. Understandably, they also report losing ... Brian Wansink, Director of the Cornell Food and Brand Lab, ...
Cached Biology News:Researchers recommend pregnant women take 4,000 IU vitamin D a day 2Scientists identify seamounts as significant, unexplored territory 2
... a compact benchtop and stackable multi-function ... with a large display screen to ... Air circulation inside to evenly distribute ... be easily calibrated from the microprocessor ...
... Biotin label transfer is fast emerging ... interaction discovery and confirmation. Until now, only ... targeted with label transfer reagents such as ... chain analog, Mts-Atf-LC-Biotin, are exciting additions to ...
... siTrio siRNA --- a cocktail of 3 ... of interestis our most popular product. The ... 75% knockdown of your target gene when ... for transfection and confirmation of optimal transfection ...
... fast emerging as a powerful new tool ... now, only amino groups have been able ... such as our Sulfo-SBED. Sulfhydryl-reactive Mts-Atf-Biotin and ... additions to the protein interaction tool chest ...
Biology Products: